FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047486793> ?p ?o ?g. }

• W2047486793 endingPage "161" @default.
• W2047486793 startingPage "151" @default.
• W2047486793 abstract "Platelets play a central role in atherosclerosis and atherothrombosis, and circulating endocannabinoids might modulate platelet function. Previous studies concerning effects of anandamide (N-arachidonylethanolamide) and 2-arachidonoylglycerol (2-AG) on platelets, mainly performed on isolated cells, provided conflicting results. We therefore investigated the action of three main endocannabinoids [anandamide, 2-AG and virodhamine (arachidonoylethanolamine)] on human platelets in blood and platelet-rich plasma (PRP). 2-AG and virodhamine induced platelet aggregation in blood, and shape change, aggregation and adenosine triphosphate (ATP) secretion in PRP. The EC50 of 2-AG and virodhamine for platelet aggregation in blood was 97 and 160 µM, respectively. Lower concentrations of 2-AG (20 µM) and virodhamine (50 µM) synergistically induced aggregation with other platelet stimuli. Platelet activation induced by 2-AG and virodhamine resembled arachidonic acid (AA)-induced aggregation: shape change, the first platelet response, ATP secretion and aggregation induced by 2-AG and virodhamine were all blocked by acetylsalicylic acid (ASA) or the specific thromboxane A2 (TXA2) antagonist daltroban. In addition, platelet activation induced by 2-AG and virodhamine in blood and PRP were inhibited by JZL184, a selective inhibitor of monoacylglycerol lipase (MAGL). In contrast to 2-AG and virodhamine, anandamide, a substrate of fatty acid amidohydrolase, was inactive. Synthetic cannabinoid receptor subtype 1 (CB1) and 2 (CB2) agonists lacked stimulatory as well as inhibitory platelet activity. We conclude that 2-AG and virodhamine stimulate platelets in blood and PRP by a MAGL-triggered mechanism leading to free AA and its metabolism by platelet cyclooxygenase-1/thromboxane synthase to TXA2. CB1, CB2 or non-CB1/CB2 receptors are not involved. Our results imply that ASA and MAGL inhibitors will protect platelets from activation by high endocannabinoid levels, and that pharmacological CB1- and CB2-receptor ligands will not affect platelets and platelet-dependent progression and complications of cardiovascular diseases." @default.
• W2047486793 created "2016-06-24" @default.
• W2047486793 creator A5015728629 @default.
• W2047486793 creator A5028428127 @default.
• W2047486793 creator A5073872763 @default.
• W2047486793 date "2013-06-21" @default.
• W2047486793 modified "2023-10-09" @default.
• W2047486793 title "Mechanism of platelet activation induced by endocannabinoids in blood and plasma" @default.
• W2047486793 cites W1495965179 @default.
• W2047486793 cites W1523926970 @default.
• W2047486793 cites W1549718010 @default.
• W2047486793 cites W1555230890 @default.
• W2047486793 cites W1583096652 @default.
• W2047486793 cites W1601972352 @default.
• W2047486793 cites W1630076867 @default.
• W2047486793 cites W1654413081 @default.
• W2047486793 cites W1891400074 @default.
• W2047486793 cites W1918234784 @default.
• W2047486793 cites W1929250398 @default.
• W2047486793 cites W1972143347 @default.
• W2047486793 cites W1975994545 @default.
• W2047486793 cites W1976340084 @default.
• W2047486793 cites W1981538767 @default.
• W2047486793 cites W2001489011 @default.
• W2047486793 cites W2003240244 @default.
• W2047486793 cites W2010949349 @default.
• W2047486793 cites W2011962376 @default.
• W2047486793 cites W2021389931 @default.
• W2047486793 cites W2026387596 @default.
• W2047486793 cites W2031828723 @default.
• W2047486793 cites W2039448868 @default.
• W2047486793 cites W2046870314 @default.
• W2047486793 cites W2051554315 @default.
• W2047486793 cites W2052101688 @default.
• W2047486793 cites W2054324237 @default.
• W2047486793 cites W2056210502 @default.
• W2047486793 cites W2056993290 @default.
• W2047486793 cites W2056993604 @default.
• W2047486793 cites W2057425748 @default.
• W2047486793 cites W2064803521 @default.
• W2047486793 cites W2068129165 @default.
• W2047486793 cites W2068437232 @default.
• W2047486793 cites W2071792310 @default.
• W2047486793 cites W2077030928 @default.
• W2047486793 cites W2077854328 @default.
• W2047486793 cites W2094918023 @default.
• W2047486793 cites W2095631860 @default.
• W2047486793 cites W2099426073 @default.
• W2047486793 cites W2108417414 @default.
• W2047486793 cites W2112253197 @default.
• W2047486793 cites W2119826244 @default.
• W2047486793 cites W2119947437 @default.
• W2047486793 cites W2132380973 @default.
• W2047486793 cites W2136242062 @default.
• W2047486793 cites W2136399145 @default.
• W2047486793 cites W2143124868 @default.
• W2047486793 cites W2143941489 @default.
• W2047486793 cites W2147929015 @default.
• W2047486793 cites W2149829923 @default.
• W2047486793 cites W2164915356 @default.
• W2047486793 cites W2416461718 @default.
• W2047486793 cites W2444018437 @default.
• W2047486793 cites W2968926214 @default.
• W2047486793 doi "https://doi.org/10.3109/09537104.2013.803530" @default.
• W2047486793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23789792" @default.
• W2047486793 hasPublicationYear "2013" @default.
• W2047486793 type Work @default.
• W2047486793 sameAs 2047486793 @default.
• W2047486793 citedByCount "31" @default.
• W2047486793 countsByYear W20474867932015 @default.
• W2047486793 countsByYear W20474867932016 @default.
• W2047486793 countsByYear W20474867932017 @default.
• W2047486793 countsByYear W20474867932018 @default.
• W2047486793 countsByYear W20474867932019 @default.
• W2047486793 countsByYear W20474867932020 @default.
• W2047486793 countsByYear W20474867932021 @default.
• W2047486793 countsByYear W20474867932022 @default.
• W2047486793 countsByYear W20474867932023 @default.
• W2047486793 crossrefType "journal-article" @default.
• W2047486793 hasAuthorship W2047486793A5015728629 @default.
• W2047486793 hasAuthorship W2047486793A5028428127 @default.
• W2047486793 hasAuthorship W2047486793A5073872763 @default.
• W2047486793 hasConcept C126322002 @default.
• W2047486793 hasConcept C134018914 @default.
• W2047486793 hasConcept C148001335 @default.
• W2047486793 hasConcept C170493617 @default.
• W2047486793 hasConcept C181199279 @default.
• W2047486793 hasConcept C185592680 @default.
• W2047486793 hasConcept C2776885963 @default.
• W2047486793 hasConcept C2778078955 @default.
• W2047486793 hasConcept C2779689624 @default.
• W2047486793 hasConcept C2779783865 @default.
• W2047486793 hasConcept C2780871563 @default.
• W2047486793 hasConcept C2781024287 @default.
• W2047486793 hasConcept C2781080829 @default.
• W2047486793 hasConcept C2781144285 @default.
• W2047486793 hasConcept C3018697912 @default.
• W2047486793 hasConcept C46721173 @default.

• next